BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Trellis Bioscience, Inc. 

2-B Corporate Drive

South San Francisco  California  94080  U.S.A.
Phone: 650-616-1100 Fax: 650-589-4860


SEARCH JOBS

Trellis Bioscience, Inc. discovers and develops novel human antibody therapeutics as treatments for infectious disease and oncology indications. The company leverages its proprietary platform technology, CellSpot™, to find rare human antibodies with superior selectivity, affinity and other drug parameters. The company is building a pipeline of monoclonal antibodies in early stage development.

Trellis is privately held and has raised $30 million from two rounds of venture funding. Investors include Series B lead investor Novartis Venture Fund, Morgenthaler Ventures, Easton Hunt Capital Partners, Sagamore BioVentures and Pac-Link BioVentures.

Our experienced executive team has a strong background in antibody discovery and development working at companies such as Genentech and Abgenix.

CellSpot™, Trellis’ proprietary technology, is a very-high throughput cell-based assay that facilitates the discovery of best-in-class antibodies optimized on multiple parameters, such as specificity, affinity, protein expression levels and immunogenicity. The technology can screen up to a million cells in a few days on 10 different parameters simultaneously, representing a 3-4 orders of magnitude improvement over other methods.

Our assay enables the discovery of antibodies that would be overlooked by traditional screening methods, such as very rare antibodies identified in and recovered from human blood cells.

Trellis is using CellSpot to discover antibodies for its own pipeline, incorporating the full set of characteristics needed to optimize their potential success as therapeutics.

RSV Program
Our furthest advanced program—at preclinical candidate selection stage—targets RSV (Respiratory Syncytial Virus) a single-stranded RNA virus that causes respiratory tract infections. While mostly producing moderate to severe cold-like symptoms, the virus may cause severe lower respiratory tract disease. Young children and the elderly are most vulnerable to severe infection, and since infection does not build immunity, people can be infected multiple times.

Oncology Programs
Trellis is also aggressively pursuing cancer targets with CellSpot and has generated antibodies at the lead optimization and lead discovery stage.

Partnerships
Trellis has an antibody discovery partnership with PDL BioPharma and seeks additional partnerships with select pharmaceutical companies. Pilot programs with multiple other partners are completed or ongoing.

Last Updated: 02-28-2008

 Key Statistics


Email: hr@trellisbio.com
Ownership: Private

Web Site: Trellis Bioscience, Inc.
Employees:
Symbol: 
 



Industry
Biotechnology






 Company News
Trellis Bioscience, Inc. and OMT Announce Therapeutic Antibody Discovery Collaboration 10/8/2012 9:51:14 AM    More...
Trellis Bioscience, Inc. Awarded SBIR Grant to Advance CMV Program 8/16/2012 10:32:50 AM    More...
MedImmune: Collaboration With Trellis Bioscience, Inc. Strengthens RSV Pipeline 12/8/2009 6:16:51 AM    More...
Trellis Bioscience, Inc. Grants MedImmune (JOBS) License for Its Anti-RSV Antibodies in Deal Worth Potentially $338 Million 12/1/2009 6:29:04 AM    More...
Trellis Bioscience, Inc.:Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow In 771 Deep Vein Thrombosis (DVT) Patients 3/19/2008 11:51:57 AM    More...
Trellis Bioscience, Inc. Appoints John Wulf as EVP, Business Operations and Chief Business Officer 1/4/2008 10:21:43 AM    More...
Trellis Bioscience, Inc. Discovers Anti-RSV Monoclonal Antibodies Isolated Directly from Human Blood Cells 10/29/2007 12:35:09 PM    More...
Trellis Bioscience, Inc. Discovers Anti-RSV Monoclonal Antibodies Isolated Directly from Human Blood Cells 10/26/2007 11:31:16 AM    More...
Trellis Bioscience, Inc. Names Bruce Keyt, Ph.D. as Chief Technology Officer and Vice President of Research 4/10/2007 11:55:04 AM    More...
Trellis Bioscience, Inc. Names Brian C. Cunningham As CEO 1/18/2007 9:42:42 AM    More...
12

//-->